Current medical management of CAD involves a two-pronged approach – to relieve symptoms and reduce the risk of cardiovascular events.

This is combined with lifestyle modification, which is an important step in both preventing CAD and improving the prognosis in patients with stable CAD.

Symptomatic treatment of CAD is intended to reduce angina symptoms and improve exercise capacity and quality of life.

  • β-blockers and calcium channel antagonists: main medicines used to lower heart rate and reduce angina symptoms.
  • Newer treatment options: selective If inhibitor: relieve angina symptoms and boost exercise capacity by selectively reducing resting heart rate

Cardioprotective therapy for CAD is aimed at reducing the risk of heart attack and heart failure, and prolonging life.
It can include:6

  • Antithrombotic therapy (eg. aspirin) : prevents blood clots forming in the coronary arteries
  • Statins: reduce cholesterol levels in the blood
  • ACE inhibitors: lower blood pressure and have additional cardiovascular effects
  • b-blockers: relieve symptoms of angina and also reduce the risk of cardiovascular death and heart attack in patients who have suffered a previous myocardial infarction
  • If inhibitor: anti-anginal effectiveness + may also reduce the risk of coronary events in CAD patients with a high resting heart rate.13

Medical procedures are also used in the treatment of CAD.

Despite lifestyle modifications, current treatment options and surgical techniques, cardiovascular disease remains a problem and there exists a clear need for new and effective preventative treatments.

Newer treatment options include selective If inhibitors which relieve angina symptoms, boost exercise capacity by selectively reducing resting heart rate, and could improve cardiovascular prognosis in coronary patients13 with elevated heart rate ( HR >70 bpm).


6. The CLARIFY Registry: Management of Stable Coronary Artery Disease in Clinical Practice. Brochure for participating doctors. Edited by G Steg on behalf of the BEAUTIFUL Executive Committee.
13. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (Beautiful): a randomized, double-blind, placebocontrolled trial. Lancet 2008, 372, 807–816.